The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
The U.S. is one of only two countries that legally allows drugmakers to advertise products directly to patients. There are ...
“We continue to transform cancer care with Kisqali, building on its established profile in the metastatic setting and now helping a wide range of people as they strive to stay cancer-free ...
Novartis said that its Kisqali drug reduces the risk of breast cancer recurrence by nearly one-third, in updated analysis from Phase 3 trials. The Swiss pharmaceutical company said Monday that its ...
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...
Eric Le Berrigaud’s rating is based on the comprehensive analysis of Novartis AG’s recent developments and market potential for its breast cancer treatment, Kisqali. The FDA’s approval of ...
Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback